Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $180,855 | $156,797 | $137,785 | $122,536 |
| % Growth | 15.3% | 13.8% | 12.4% | – |
| Cost of Goods Sold | $83,591 | $71,021 | $61,658 | $66,173 |
| Gross Profit | $97,264 | $85,763 | $76,127 | $56,363 |
| % Margin | 53.8% | 54.7% | 55.3% | 46% |
| R&D Expenses | $24,139 | $18,753 | $19,325 | $35,127 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $49,104 | $46,863 | $43,530 | $40,535 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $73,243 | $65,616 | $62,855 | $75,662 |
| Operating Income | $24,021 | $20,160 | $13,272 | -$19,299 |
| % Margin | 13.3% | 12.9% | 9.6% | -15.7% |
| Other Income/Exp. Net | $3,136 | $2,717 | $2,293 | $2,320 |
| Pre-Tax Income | $27,157 | $22,877 | $15,565 | -$16,979 |
| Tax Expense | $8,722 | $5,045 | $7,026 | -$8,091 |
| Net Income | $18,435 | $17,832 | $8,539 | -$8,888 |
| % Margin | 10.2% | 11.4% | 6.2% | -7.3% |
| EPS | 0.25 | 0.24 | 0.12 | -0.12 |
| % Growth | 4.2% | 100% | 200% | – |
| EPS Diluted | 0.23 | 0.23 | 0.11 | -0.12 |
| Weighted Avg Shares Out | 73,606 | 73,439 | 72,647 | 72,319 |
| Weighted Avg Shares Out Dil | 78,027 | 77,942 | 76,146 | 72,319 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2,717 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $384 | $358 | $345 | $400 |
| EBITDA | $27,541 | $20,518 | $13,617 | -$16,579 |
| % Margin | 15.2% | 13.1% | 9.9% | -13.5% |